Aubier M, Lode H, Gialdroni-Grassi G, Huchon G, Hosie J, Legakis N, Regamey C, Segev S, Vester R, Wijnands W J, Tolstuchow N
Hôpital Bichat 8 SUD, Service de Pneumologie, Paris, France.
J Antimicrob Chemother. 1996 May;37 Suppl A:73-82. doi: 10.1093/jac/37.suppl_a.73.
A pooled data analysis of two double-blind studies encompassing 1137 episodes of community-acquired pneumonia in hospitalised adults, of which 560 were treated with sparfloxacin and 577 were randomised to comparator antibacterial agents (amoxycillin/clavulanic acid, erythromycin or amoxycillin administered at reference dosages), was performed. The global efficacy rate at the end of treatment in evaluable patients treated with sparfloxacin was 88.3% compared with 84.1% in those who received comparator antibacterial agents. This analysis verified the efficacy of this new aminofluoroquinolone, given orally once daily, in the treatment of community acquired pneumonia. The overall outcome favoured sparfloxacin for use in the empirical treatment of community-acquired pneumonia.
对两项双盲研究进行了汇总数据分析，这些研究涵盖了1137例住院成人社区获得性肺炎病例，其中560例接受司帕沙星治疗，577例被随机分配至对照抗菌药物组（阿莫西林/克拉维酸、红霉素或按参考剂量给药的阿莫西林）。接受司帕沙星治疗的可评估患者在治疗结束时的总体有效率为88.3%，而接受对照抗菌药物治疗的患者为84.1%。该分析证实了这种每日口服一次的新型氨基氟喹诺酮在治疗社区获得性肺炎方面的疗效。总体结果支持司帕沙星用于社区获得性肺炎的经验性治疗。
